Oncimmune stock price, funding rounds, valuation and financials

Oncimmune has raised $15 m in total funding. Oncimmune annual revenue was £104 k in FY 2018

£104 K

Oncimmune Revenue FY, 2018
Oncimmune Gross profit (FY, 2018)-154 K
Oncimmune Gross profit margin (FY, 2018), %(148.1%)
Oncimmune Net income (FY, 2018)-5 M
Oncimmune EBITDA (FY, 2018)3.3 M
Oncimmune EBIT (FY, 2018)3.2 M
Oncimmune Cash, 31-May-20188.5 M

Oncimmune Funding

Summary Metrics

Founding Date

2006

Oncimmune total Funding

$15 m

Oncimmune latest funding size

$15 m

Time since last funding

3 years ago

Oncimmune investors

Oncimmune's latest funding round in January 2017 was reported to be $15 m. In total, Oncimmune has raised $15 m

Oncimmune Capital Raised

Embed Graph

Oncimmune Income Statement

Annual

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.4k15.4k55.0k149.4k1.5m1.1m1.3m303.0k80.0k104.0k

Revenue growth, %

(31%)27%(77%)

Cost of goods sold

136.3k140.5k2.9k248.0k258.0k

Gross profit

1.4m916.4k1.3m(168.0k)(154.0k)

Gross profit Margin, %

91%87%100%(210%)(148%)

Operating expense total

1.8m6.3m4.6m4.6m4.5m3.7m2.7m3.1m3.1m(3.3m)

EBITDA

(2.6m)(4.1m)(6.4m)(5.8m)(4.2m)(4.2m)(2.9m)(2.7m)(1.3m)(2.7m)(3.3m)3.3m

EBITDA margin, %

(37880%)(7548%)(2783%)(189%)(257%)(100%)(893%)(4070%)3184%

EBIT

(209.2k)(579.9k)(1.8m)(2.7m)(4.3m)(6.8m)(6.3m)(4.6m)(4.5m)(3.1m)(2.8m)(1.4m)(2.7m)(3.3m)3.2m

EBIT margin, %

(131382%)(41229%)(8284%)(2999%)(201%)(261%)(103%)(908%)(4100%)3059%

Pre tax profit

(198.9k)(546.9k)(1.5m)(2.6m)(4.2m)(6.8m)(6.4m)(4.6m)(4.6m)(3.2m)(1.6m)(2.0m)(2.4m)(4.3m)(5.0m)

Income tax expense

261.8k204.2k343.4k320.1k124.5k166.6k181.4k565.0k293.0k

Net Income

(198.9k)(546.9k)(1.5m)(2.6m)(3.9m)(6.6m)(6.1m)(4.3m)(4.4m)(3.0m)(1.4m)(2.0m)(1.8m)(4.0m)(5.0m)

Oncimmune Balance Sheet

Annual

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

11.5k1.0m4.0m3.3m3.0m3.7m5.3m2.7m2.1m1.1m1.6m1.3m10.1m4.9m8.5m

Accounts Receivable

1.6k334.1k118.8k265.4k28.0k16.0k22.0k

Inventories

116.1k91.0k83.0k

Current Assets

19.8k1.0m4.2m3.4m3.2m3.8m6.4m2.8m2.3m1.9m2.4m1.9m10.5m5.1m8.8m

PP&E

862.02.2k209.2k746.6k1.3m1.3m940.9k455.4k255.4k154.5k65.8k48.1k11.0k7.0k8.0k

Goodwill

30.0k131.0k

Total Assets

20.6k1.0m4.4m4.1m4.6m5.0m7.3m3.3m2.6m2.0m2.5m2.0m11.1m6.1m9.9m

Accounts Payable

29.2k34.9k151.5k51.0k187.5k111.6k558.8k218.3k135.1k283.9k290.8k200.2k368.0k401.0k257.0k

Current Liabilities

68.7k98.6k505.5k120.3k520.3k490.1k1.5m638.5k723.7k2.4m1.1m1.6m15.9m15.3m24.1m

Non-Current Liabilities

150.0k411.8k1.0m1.2m1.4m1.2m1.2m3.2m4.1m395.0k

Total Debt

120.1k

Total Liabilities

218.7k98.6k505.5k532.1k1.5m1.7m2.9m1.9m2.0m2.4m4.3m5.7m16.3m15.3m24.1m

Common Stock

810.01.5k2.5k2.9k3.2k3.7k5.4k5.6k6.5k7.0k7.0k7.0k7.0k7.0k7.0k

Retained Earnings

(30.3m)(31.8m)(33.7m)(34.4m)(38.4m)(43.4m)

Total Equity

(198.1k)920.2k3.9m3.6m3.0m3.3m4.4m1.4m589.5k(363.7k)(1.8m)(3.7m)(5.2m)(9.2m)(14.2m)

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

-0.1 x1.1 x1.1 x1.1 x1.5 x1.5 x1.6 x2.3 x4.3 x-5.5 x-1.4 x-0.5 x-2.2 x-0.7 x-0.7 x

Oncimmune Cash Flow

Annual

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(198.9k)(546.9k)(1.5m)(2.6m)(3.9m)(6.6m)(6.1m)(4.3m)(4.4m)(3.0m)(1.4m)(2.0m)(1.8m)(4.0m)(5.0m)

Cash From Operating Activities

(3.4m)(5.3m)(4.7m)(4.5m)(4.1m)(3.2m)(2.3m)(1.4m)

Cash From Financing Activities

3.6m5.5m5.9m1.6m3.5m2.0m1.8m1.2m

Net Change in Cash

(348.2k)439.7k1.6m(2.6m)(534.9k)(1.1m)557.5k(310.3k)

Income Taxes Paid

181.4k565.0k

Oncimmune Ratios

GBPY, 2018

Revenue/Employee

3.0k

Financial Leverage

-0.7 x